Eli Lilly to Acquire CrossBridge Bio for up to $300M

Why It Matters

The acquisition bolsters Lilly’s pipeline in the fast‑growing ADC market, giving it a competitive edge and a new revenue stream as oncology drives pharma growth.

Key Takeaways

• Lilly pays up to $300 M for CrossBridge’s ADC platform
• CrossBridge’s lead candidate is in Phase 1/2 trials
• Deal adds a novel antibody‑drug conjugate pipeline to Lilly
• Acquisition aligns with Lilly’s precision‑oncology strategy
• Closing targeted for Q4 2024

Pulse Analysis

The global antibody‑drug conjugate market is projected to exceed $15 billion by 2028, fueled by demand for targeted cancer therapies that minimize systemic toxicity. Major players such as Roche, AstraZeneca and Pfizer have poured billions into ADC research, making platform ownership a strategic priority. Eli Lilly, already a stakeholder in this space with its FDA‑approved ADC Enhertu, has been seeking to broaden its portfolio to capture a larger share of the high‑margin oncology segment.

CrossBridge Bio, founded by PhD biologist Michael Torres, has developed a proprietary linker‑technology that promises higher payload stability and improved tumor selectivity. Its lead candidate, an ADC aimed at a prevalent solid‑tumor antigen, has shown encouraging safety and early efficacy signals in Phase 1/2 studies. The technology’s modular design allows rapid pairing with multiple antibodies, giving Lilly a versatile toolkit to address a range of tumor types without starting from scratch.

Strategically, the acquisition positions Lilly to compete more aggressively against rivals that have recently secured similar platforms. By integrating CrossBridge’s assets, Lilly can accelerate its pipeline, potentially bringing new ADCs to market within the next three to five years and generating incremental revenue streams. The deal also reflects a broader industry trend of big pharma buying innovative biotech firms to stay ahead in the precision‑medicine race, underscoring the importance of early‑stage technology platforms in shaping future oncology growth.

Deal Summary

Eli Lilly announced on Tuesday it will acquire cancer‑focused antibody‑drug conjugate startup CrossBridge Bio for up to $300 million. The deal, involving biotech entrepreneur Michael Torres, aims to strengthen Lilly’s oncology pipeline. The acquisition was disclosed on 14 April 2026.